LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CORT&src=ctag” target=”_blank”gt;$CORTlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf
of Corcept Therapeutics Incorporated investors (“Corcept” or the
“Company”) (NASDAQ: CORT)
concerning the Company and its officers’ possible violations of federal
If you are a shareholder who suffered a loss, click here
On January 25, 2019, Southern Investigative Reporting Foundation (SIRF)
published a report alleging that Corcept paid doctors to prescribe its
drug Korlym for off-label uses in 2016 – 2017. The report condemned
the company for exploiting regulatory loopholes, charging patients an
excessive price for its lone drug product, and touting evidence for the
drug’s effectiveness that – according to SIRF – doesn’t exist. On this
news, shares of Corcept fell $1.52, or 11%, to close at $12.29 on
January 25, 2019, thereby injuring investors.
If you purchased Corcept stock, have information, or would like to learn
more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite
2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.